C-SWITCH
Financiado
CTP-dependent molecular switches: an emerging new principle in cellular regulati...
Nucleotide-dependent molecular switches play key roles in the regulation of cellular processes such as translation, protein folding and transport, cytoskeletal dynamics and cell differentiation. Until recently, their function was...
Nucleotide-dependent molecular switches play key roles in the regulation of cellular processes such as translation, protein folding and transport, cytoskeletal dynamics and cell differentiation. Until recently, their function was thought to rely exclusively on the purine nucleotides GTP or ATP as cofactors. This paradigm changed in 2019, when my group identified a fundamentally new class of regulatory switches, now called C-switches, that depend on the pyrimidine nucleotide CTP.The few C-switches studied to date have important functions in bacterial growth and pathogenicity. Database searches predict that C-switches are highly diverse and widespread in nature. However, the physiological roles and modes of action of these proteins are still largely enigmatic. The overarching goal of C SWITCH is to provide comprehensive insight into the biology of C-switches and clarify the ways in which this newly identified regulatory principle can control protein activity and cellular functions. For this purpose, we will employ both bioinformatic and experimental methods to systematically identify new types of C-switch proteins and perform detailed mechanistic studies of prototypic representatives, using state-of-the-art in vitro and in vivo approaches. C-SWITCH will thus break new ground in the understanding of cellular regulation and pave the way to a global understanding of C-switches as versatile regulators in biology. Importantly, proteins containing a canonical C-switch domain are absent from humans and other mammalian systems. C-SWITCH will therefore also explore the pharmacological potential of C-switches as new targets for antibacterial and antivirulence therapies, thereby possibly opening new avenues for translational applications and supporting the current global effort to combat bacterial antibiotic resistance.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2023-10-01
Fecha Fin: 2028-09-30
Fecha Fin: 2028-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
PHILIPPS UNIVERSITAET MARBURG
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5